Syros Pharmaceuticals Inc. | Mutual Funds
Mutual Funds that own Syros Pharmaceuticals Inc.
ARK Innovation ETF
1,319,081
3.92%
0
1.14%
09/05/2018
Fidelity Growth Company Fund
1,150,154
3.42%
-6,240
0.03%
07/31/2018
Fidelity Select Biotechnology Portfolio
617,861
1.84%
0
0.08%
07/31/2018
Vanguard Total Stock Market Index Fund
560,824
1.67%
31,199
0%
07/31/2018
iShares Russell 2000 ETF
512,615
1.52%
-273
0.01%
09/06/2018
ARK Genomic Revolution Multi Sector ETF
476,497
1.42%
2,660
1.9%
09/05/2018
Fidelity Series Growth Company Fund
324,829
0.97%
0
0.03%
07/31/2018
Vanguard Extended Market Index Fund
274,221
0.82%
0
0.01%
07/31/2018
iShares Russell 2000 Growth ETF
229,877
0.68%
0
0.03%
09/06/2018
Fidelity Advisor Biotechnology Fund
170,750
0.51%
0
0.07%
07/31/2018
| Address |
620 Memorial Drive
Cambridge Massachusetts 02139
United States
|
|
Employees
|
- |
| Website |
http://www.syros.com |
| Updated |
07/08/2019 |
| Syros Pharmaceuticals, Inc. engages in the development of novel gene control therapies for cancer and other diseases. It has developed a proprietary platform that is designed to systematically and efficiently analyze unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations. The company focuses on developing treatments for cancer and immune mediated diseases and is building a pipeline of gene control medicines. |
